Corvus Pharmaceuticals, Inc.
CRVS
$3.22
-$0.02-0.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 69.88% | -843.62% | 25.24% | 14.31% | -10.88% |
| Total Depreciation and Amortization | -4.76% | 0.00% | -8.70% | -17.86% | -6.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -84.92% | 4,954.24% | -330.13% | -83.67% | 58.58% |
| Change in Net Operating Assets | -1,157.25% | 125.32% | -348.86% | 156.01% | 37.94% |
| Cash from Operations | -33.92% | -15.33% | -6.28% | 0.19% | 4.91% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -56.50% | 77.78% | -249,957.14% | 99.70% | -113.21% |
| Cash from Investing | -56.38% | 77.78% | -249,957.14% | 99.70% | -113.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 37,116.00% | -99.70% | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Financing | 37,116.00% | -99.84% | -- | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 139.96% | -237.59% | 243.01% | 31.01% | -160.13% |